Form 4: IGM Biosciences Director Acquires Stock Options

Sentiment:

SEC Form 4


Director Elizabeth H.Z. Thompson acquired stock options in IGM Biosciences, Inc. on March 12, 2024.

Summary

  • On March 12, 2024, Elizabeth H.Z. Thompson, a director of IGM Biosciences, Inc., acquired 29,400 stock options.
  • The exercise price of these options is $9.95.
  • The options vest monthly following the Issuer's 2024 Annual Meeting of Stockholders, with full vesting no later than the 2025 Annual Meeting of Stockholders, contingent on continued service.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, indicating a neutral sentiment.

Future Outlook

The options vest monthly following the Issuer's 2024 Annual Meeting of Stockholders, with full vesting no later than the 2025 Annual Meeting of Stockholders, contingent on continued service.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.

Stakeholder Impact

  • The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to increase shareholder value.

Key Dates

DateDescription
03/12/2024Date of transaction: Director acquired stock options.
03/12/2024Stock options become exercisable.
03/14/2024Date of signature for the Form 4 filing.
03/12/2034Expiration date of the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.